Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.
Click the orange button to the right to learn more about what you can start doing today.
Hi David- I’m wondering your perception on the best modality to strengthen bones for a multiple myeloma bone health. I’ve heard about Denosumab, and would be interested in your thoughts on it.
Per CRAB acronym, only the Bone part has showed up in my blood work.
Thank You Abundantly! Monica
“Prescribers are advised that zoledronic acid is associated with reports of renal impairment and renal failure, especially in patients with pre-existing renal dysfunction…”
“In a phase III trial reported in The Lancet Oncology, Raje et al found that denosumab was noninferior to zoledronic acid in preventing skeletal-related events (SREs) in newly diagnosed multiple myeloma patients with bone disease…
The most common grade ≥ 3 adverse events in the denosumab vs zoledronic acid groups were
Renal toxicity was reported in 10% vs 17%. Any-grade hypocalcemia occurred in 17% vs 12%. Osteonecrosis of the jaw occurred in 4% vs 3% (P = .147). The most common serious adverse event in both groups was pneumonia (8% in both). One patient in the zoledronic acid group died of cardiac arrest that was considered treatment-related.